A REVIEW OF ABBV-744 IN COMBINATION WITH IMMUNOTHERAPY

The existing work examined the potential of employing ARV-825 and ABBV-744 to boost the effectiveness of tamoxifen or fulvestrant as well as palbociclib. ARV-825 was effective in each p53 wild-variety (WT) breast tumor cells As well as in cells missing useful p53 possibly by itself or in combination with tamoxifen, whilst the effectiveness of ABBV-